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ABSTRACT
Background. Despite significant advances in haemodialysis (HD) in recent decades, current dialysis techniques are limited by
inadequate removal of uraemic solutes such as middle molecules and protein-bound uraemic toxins. Novel medium cut-off
(MCO) membrane or ‘expanded haemodialysis’ (HDx) provides diffusive removal of conventional and large middle
molecular weight uraemic toxins, with marginal albumin leak.
Methods. This prospective, open-label, controlled, cross-over pilot study compared HDx (novel MCO membrane TheranovaVR
400) and conventional HD in 20 prevalent HD patients. Biochemical, dialysis adequacy and safety measures (adverse events,
infections and hospitalization frequency) were recorded. Ten patients underwent conventional HD high-flux dialyser and
10 patients underwent HDx for 3 months, and the patients then switched and received the other treatment for a further
3 months.
Results. Treatment with HDx was associated with a significant reduction in serum albumin concentration [median
(interquartile range) reduction 0.45 g/dL (0.575 to 0.05); P¼0.025]. However, median albumin levels were 3.5 g/dL and
no patients had clinical symptoms of hypoalbuminaemia or needed intravenous albumin administration. The number of
infections was lower in patients treated with HDx (n¼7/19) compared with patients treated with HD (n¼14/20; P¼0.03).
Patients treated with HDx had reduced levels of interleukin (IL)-1b (from 0.066 0.02 pg/mL versus 0.286 0.18 pg/mL with HD)
and IL-6 (6.456 1.57 pg/mL versus 9.4862.15 pg/mL), while tumour necrosis factor-a levels remain unchanged.
Conclusions. This study demonstrates that the chronic use of the novel MCO dialyser TheranovaVR appears to be safe and
well-tolerated, without serious side effects or hypoalbuminaemia, as well as fewer infections. These results need to be
confirmed in larger randomized clinical trials.
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INTRODUCTION
Haemodialysis (HD) has made important advances in recent
decades, leading to longer survival and better quality of life in
patients with end-stage renal disease (ESRD). However, rates of
hospitalization and mortality in dialysis patients are still higher
than in the general population [1]. Patients treated with dialysis
are hospitalized on average twice a year [2], mainly due to infec-
tious diseases or vascular access issues [3]. Annual mortality in
dialysis patients is 15–20% [4], and the main causes of death
are cardiovascular diseases (50%), septicaemia and infections
(11%), and malignancies (4%). These data confirm that HD is still
a suboptimal treatment. Indeed, current dialysis techniques still
have important limitations in adequately removing some of the
uraemic solutes such as middle molecules and protein-bound
uraemic toxins [1].
Middle molecules are organic compounds characterized by a
molecular weight >500 kDa, which can accumulate in ESRD and
exert many toxic effects. The retention of middle molecules is
associated with the development of cardiovascular disease,
chronic inflammatory disease, chronic kidney disease–mineral
and bone disorder (CKD-MBD), secondary immunodeficiency,
amyloidosis and protein-energy wasting [5–9]. Therefore, a bet-
ter clearance of these toxins could lead to improved long-term
outcomes in patients with ESRD.
Several attempts have been made to enhance the removal of
conventional and large middle molecular weight uraemic toxins
through dialysis. Online haemodiafiltration provides a good
clearance of middle molecules, but the use of this technique is
limited by the need for high blood flows and accurate monitor-
ing of devices [10]. Also, high cut-off membranes can be used to
remove efficiently middle molecules from the bloodstream, but
this treatment is also associated with protein loss, and its
chronic use leads to hypoalbuminaemia [2]. Instead, the new
medium cut-off (MCO) membranes provide diffusive and to
some extent convective removal of solutes of molecular weight
up to 45 kDa, with only marginal albumin leak.
The MCO membranes have a tight pore size distribution
resulting in a steep sieving curve, with the values of molecular
weight retention onset and molecular weight cut-off very close
to each other, and with a cut-off value close to but lower than
that of albumin [1]. Due to these novel membrane characteris-
tics, the treatment with MCO membranes ‘expands’ the spec-
trum of uraemic toxins that can be removed by HD, and
therefore this novel treatment modality is called ‘expanded HD’
(HDx).
The aim of this pilot study is to compare HDx (using the new
MCO membrane TheranovaVR 400) and bicarbonate dialysis in
prevalent HD patients based on haematochemical values, in-
flammatory markers, parameters of dialysis adequacy, inci-
dence of adverse events, incidence of infections, number and
causes of hospitalization.
MATERIALS ANDMETHODS
Patients and study design
Twenty prevalent HD patients participated in this prospective,
open-label, controlled, cross-over pilot study. The study was un-
dertaken in our Dialysis Unit, University of Milan, Italy from 1
October 2017 to 31 December 2018. Consecutively, unselected
male and female adult patients with ESRD on HD were eligible
for participation in the study. Participation in the study was vol-
untary. Patients presenting with cachexia or cancer were
excluded. Patients were discretionarily divided into two groups
(A and B), with similar mean age, male–female ratio and dialytic
vintage. This was a cross-over design whereby patients in
Group A were treated with Theranova dialyser (HDx) for the first
3 months of the study, and then switched to conventional bicar-
bonate dialysis for the remaining 3 months. Patients in Group B
were treated with bicarbonate dialysis for the first 3 months of
the study, and then switched to HDx for the next 3 months
(Figure 1). Sera samples from both groups were collected at 1, 2
and 3 months. This study complies with the ethical standards of
the 1975 Declaration of Helsinki and the study was approved by
the local Ethical Committee. This study is registered at
ClinicalTrials.gov. The registration identification number is
NCT03169400. All patients provided written informed consent
before inclusion in the study, in compliance with Italian
Legislative Decree (L. 675/1996).
Dialysis materials
All treatments were provided by FreseniusVR 5008 (Fresenius
5008, Fresenius Medical Care, Bad Homburg, Germany). A novel
membrane, TheranovaVR 400 (Baxter, USA), was used for patients
undergoing HDx, while various other membranes (FX8, FX10,
FX80, FX100, BK1.6, BG2.1), based on clinical needs, were used in
patients undergoing bicarbonate dialysis.
Clinical outcome measures
Hypotension was defined as an episode of at least one symp-
tomatic blood pressure reduction [decrease in systolic blood
pressure (SBP) by 20 mmHg or a decrease in mean arterial
pressure by 10 mmHg] at any time during the dialysis session,
recorded by nurse staff into clinical records [11]. An infective
event was defined as an episode characterized by clinical signs
and symptoms necessitating antibiotic therapy. Hospitalization
was defined as any hospital admission resulting in inpatient
status for 24 h or longer.
Determination of cytokine levels
Levels of serum inflammatory cytokines were quantified using
Quantikine HS ELISA kits for human interleukin (IL)-6 (HS600C)
and for IL-1b (HSLB00D) (R&D Systems, Minneapolis, MN, USA).
Briefly, frozen human sera were thawed at 4C and centrifuged
at 16 000g for 2 min and 100 mL were used for the assay.
Following the addition of substrate, colorimetric change was de-
termined by the absorbance value measured at 450 nm.
Statistical analysis
Data are presented as mean6SD for continuous variables, and
median and interquartile range (IQR) for not normally distrib-
uted variables. Comparisons between Groups A and B were per-
formed by the Fisher’s exact test for categorical variables or
Mann–Whitney U test for continuous variables. Comparisons of
continuous variables between treatments within the same
groups were performed by the Wilcoxon signed-rank test. The
association between changes in serum albumin levels, as de-
pendent variable, and treatment, time and time  treatment in-
teraction (predictors) was performed using a regression model.
The frequency of clinical outcome measures (hypotension, in-
fection and hospitalization) was arbitrarily categorized into sub-
classes. The association between the frequency of events
(dependent variable) and treatment, time and their interaction
(predictors) was subsequently analysed by generalized linear
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models (for dichotomous dependent variables) or ordinal logis-
tic regression models (for dependent variable with more than
two levels). A P< 0.05 was considered statistically significant.
All analysis was performed using R 3.2.1 GUI 1.6 and STATA 11.2
software (Statacorp LP Inc., College Station, TX, USA).
RESULTS
Patients
Baseline characteristics of patients are shown in Table 1. The
majority of patients were male (n¼ 16, 76%) and mean age was
71613 years with median dialysis vintage of 27 months. Co-
morbid diseases such as hypertension (86%), dyslipidaemia
(71%) and diabetes (48%) were highly prevalent in these
patients. Both groups of patients were well-matched for age, di-
alysis vintage and comorbid diseases.
Drop-outs
During the third month of the study, one patient in Group B was
relocated to another dialysis centre. This patient was still in-
cluded in the final analysis. At the time of switching treatment,
one patient could not change to HDx because of previous aller-
gic reactions to polysulphone and therefore, another prevalent
HD patient was enrolled for the second part of the study. One
patient died during the fourth month of the study. During the
fifth month of the study, one patient needed a lower flux and
discontinued treatment with HDx. Taking into consideration
the aforementioned drop-out rate, biochemical parameters
were available at the beginning and at the end of each study pe-
riod in 10 patients in Group A. For Group B, biochemical param-
eters were available for 10 patients for the entire first period
and at the beginning of the second study period, while they
were available for 8 patients during the second study period.
HD treatment
HD treatment parameters during follow-up are summarized in
Table 2. In Group B, dialytic parameters at the end of the sixth
month were limited to seven patients due to two drop-outs and
the lack of dialytic parameters at the end of the study in one
patient.
No significant differences between the two groups were ob-
served throughout the study, except for higher Kt/V values in
Group A, which attained statistical significance only within the
third month of the first study period. A non-significant decrease
in inter-dialysis weight gain during HDx treatment in Group A
and increase under HD treatment in Group B was also observed.
A non-significant trend towards higher SBP was detected in
Group B prior to treatment (Table 3), without further variations
throughout the study by both HD and HDx treatments (Table 3).
Haematological and biochemical parameters
Haematological parameters did not significantly change during
the study and did not differ between the treatment groups, with
the exception of a greater iron saturation detected in the Group
B at the end of the study (Table 4). Serum albumin levels were
maintained in patients in Group A during both treatments,
while patients in Group B showed a decrease in albumin con-
centration following treatment with HDx compared with HD. A
median (IQR) reduction in circulating albumin of 0.45 g/dL
(0.575 to 0.05) was observed within Group B during the HDx
period compared with an increase of 0.34 g/dL (0.125–0.40) under
HD (P¼ 0.025; Figure 2), after exclusion of two patients without
available albumin levels at the end of the study. In a multivari-
ate regression model, the change in albumin levels was not pre-
dicted by treatment (P¼ 0.50), study period (P¼ 0.38) and their
interaction (P¼ 0.67).
Inflammatory cytokines
Levels of sera IL-1b were higher in Group A under HD com-
pared with HDx, but this difference was not statistically signif-
icant (0.12 pg/mL versus 0.076 0.016 pg/mL; P¼ 0.16). Similarly,
IL-1b levels were reduced under HDx versus HD in Group B,
but this difference was not statistically significant
(0.0576 0.027 pg/mL versus 0.2860.17 pg/mL; P¼ 0.16)
(Figure 3A). IL-6 levels slightly increased following HD com-
pared with patients under HDx in Group A (10.96 2.3 pg/mL
versus 6.761.7 pg/mL; P¼ 0.15) and reduced in HDx patients
versus those under HD in Group B (6.561.6 pg/mL versus
9.562.2 pg/mL; P¼ 0.28), but this difference did not attain sta-
tistical significance (Figure 3B).
Hypotension
Data concerning intra-dialytic hypotension were available in 10
patients for Group A for both study periods, 10 patients of Group
B during the first study period and 8 patients of Group B during
the second study period (due to the two aforementioned drop-
outs). A total of 110 hypotensive episodes were recorded in a to-
tal of 16 individual patients. The frequency of hypotension per
patient was categorized into four classes: absent, low (one epi-
sode/patient), middle (two to three episodes/patient) and high
(more than four episodes/patient) (Figure 4A). In eight patients,
there was a higher incidence of intra-dialytic symptomatic hy-
potensive events during HDx compared with five events
recorded for HD (Figure 4A). However, the total number of ab-
sent/low hypotensive events was 11 during HD versus 9 in HDx,
and patients in both treatment groups had the same number of
moderate or high hypotensive events (n¼ 9). Multivariate analy-
sis revealed that HD was associated with a non-significant trend
towards a lower risk of hypotension, independently from time
and time  treatment interaction [odds ratio (OR) 0.22, 95% con-
fidence interval (CI) 0.04–1.20; P¼ 0.074]. The effect of treatment
was lost in a model including group effect (data not shown).
Infections
Data related to infective episodes were available for 10 patients
in Group A for both study periods, 9 patients in Group B during
the first study period and 10 patients in Group B during the sec-
ond study. A total of 27 infective episodes were reported among
10 individual patients. Detailed frequency of infection is
summarized in Supplementary data, Table S1. The frequency of
infection per patient was categorized into two classes: none and
FIGURE 1: Study design.
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one or more infection/patient (Figure 4B). The total number of
infections was lower during treatment with HDx than with HD
(n¼ 7/19 versus n¼ 14/20; P¼ 0.03). As shown in Figure 4B, a
higher risk of developing one or more infection was observed
during HD (n¼ 6/19 versus n¼ 14/20; P¼ 0.026) treatment than
during HDx (OR 5.04, 95% CI 1.35–21.16; P¼ 0.020), independently
of the effect of time and groups.
Hospitalization
Patients hospitalized included 10 patients in Group A during
both study periods, 9 patients in Group B during the first study
period and 10 patients in Group B during the second study pe-
riod. A total of 19 hospitalizations were recorded. Causes of hos-
pitalization are summarized in Supplementary data, Table S2.
The frequency of hospitalizations was categorized into the
Table 2. Dialytic parameters of Groups A and B during treatment with HDx (black) and HD (grey)
Kt/V QB (mL/min) DBW (kg)
Month Group A Group B P-value Group A Group B P-value Group A Group B P-value
1 1.18 (1.14–1.20) 1.03 (0.95–1.15) 0.121 297 (286–301) 283 (248–309) 0.796 2.39 (2.09–2.61) 2.01 (1.35–2.91) 0.739
2 1.16 (1.12–1.23) 1.02 (0.99–1.13) 0.089 295 (283–301) 292 (264–307) 0.971 2.23 (1.81–2.58) 2.51 (1.39–3.13) 0.739
3 1.17 (1.12–1.18) 1.02 (0.93–1.09) 0.031 295 (289–307) 293 (246–311) 0.762 2.03 (1.67–2.37) 2.61 (1.90–3.22) 0.257
4 1.11 (1.09–1.15) 1.07 (0.90–1.21) 0.657 301 (291–310) 289 (263–304) 0.515 2.06 (1.78–2.58) 2.98 (2.38–3.29) 0.286
5 1.12 (1.10–1.18) 1.10 (1.01–1.11) 0.435 296 (288–310) 284 (265–298) 0.407 2.00 (1.58–2.41) 3.23 (3.08–3.44) 0.089
6 1.12 (1.03–1.15) 1.12 (1.01–1.22) 0.769 296 (275–304) 280 (256–302) 0.475 2.06 (1.36–2.65) 3.02 (2.09–3.45) 0.222
Values are presented as median (IQR). P-values refer to difference between Groups A and B at each month (Mann–Whitney U test).
DBW, body weight gain during the long interval; QB, blood flow.
Table 1. Baseline clinical characteristics of patients
Characteristic All (n¼ 21) Group A (n¼ 10) Group B (n¼ 11) P-value
General
Male gender, n (%) 16 (76) 7 (70) 9 (82) 0.635
Age, years 716 13 716 15 71613 0.916
Current smoker, n (%) 3 (14) 2 (20) 1 (9) 0.587
Ex-smoker, n (%) 4 (19) 1 (10) 3 (27) 0.597
Dialysis vintage, months 27 (15–37) 27 (18–33) 18(14–39) 0.805
Access, n (%)
Fistula 8 (38) 3 (30) 5 (45) 0.659
Central venous catheter 13 (62) 7 (70) 6 (55) 0.659
Comorbid diseases
Hypertension, n (%) 18 (86) 9 (90) 9 (82) 1.000
Diabetes, n (%) 10 (48) 5 (50) 5 (45) 1.000
Dyslipidaemia, n (%) 15 (71) 8 (80) 7 (64) 0.635
BMI (kg/m2) 23.96 2.9 23.56 3.3 24.462.5 0.870
Data are presented as mean6SD unless and otherwise specified. Dialysis vintage is presented as median (IQR).
BMI, body mass index.
Table 3. Blood pressure parameters in Groups A and B during treatment with HDx (black) and HD (grey)
Month Group A Group B P-value Group A Group B P-value
SBP start (mmHg) DBP start (mmHg)
1 136 (126–140) 145 (140–152) 0.063 63 (57–70) 61 (59–68) 0.796
2 138 (121–147) 151 (140–168) 0.052 66 (61–70) 64 (58–68) 0.739
3 136 (124–149) 148 (142–156) 0.063 63 (55–69) 64 (62–68) 0.796
4 133 (122–146) 142 (134–159) 0.145 61 (57–66) 64 (62–72) 0.451
5 133 (114–145) 146 (138–150) 0.133 64 (57–69) 63 (60–73) 1.000
6 131 (115–141) 143 (139–148) 0.161 62 (58–68) 64 (62–69) 0.601
SBP end (mmHg) DBP end (mmHg)
1 139 (120–150) 154 (148–161) 0.105 67 (56–74) 71 (64–74) 0.491
2 131 (125–146) 157 (137–169) 0.123 65 (61–73) 72 (66–79) 0.345
3 133 (116–159) 155 (136–168) 0.143 67 (60–78) 72 (64–79) 0.529
4 146 (120–159) 151 (141–166) 0.515 70 (60–73) 74 (72–78) 0.155
5 140 (117–159) 150 (138–155) 0.669 69 (63–75) 74 (69–77) 0.601
6 138 (117–162) 148 (135–153) 0.962 68 (59–74) 70 (65–73) 0.845
Values are presented as median (IQR). P-values refer to difference between Groups A and B at each month (Mann–Whitney U test).
DBP, diastolic blood pressure.
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Table 4. Haematological and biochemical parameters at the beginning of the study, at cross-over and at the end of the study
Parameter All (n¼ 20) Group A (n¼ 10) Group B (n¼ 10) P-value
Baseline
Haemoglobin, g/dL 11.0 (10.4–11.7) 11.5 (10.6–12.2) 10.7 (9.9–11.1) 0.19
Haematocrit, vol% 35.1 (34.0–37.7) 37.6 (34.4–38.4) 34.7 (31.8–35.5) 0.16
MCV, fL 98 (93–100) 98 (91–101) 97 (94–99) 1.00
WBC, 103/mL 6.76 (5.90–8.18) 6.93 (5.88–8.05) 6.76 (6.26–8.25) 0.85
Platelets, 103/mL 217 (184.5–255.3) 199 (155.3–290.5) 225.5 (206.5–243.5) 0.39
Ferritin, ng/mL 233 (149–405) 313 (201–416) 210 (139–237) 0.39
Iron, mg/dL 52 (44–65) 63 (52–68) 45 (35–53) 0.10
Iron saturation, % 24 (19–30) 26 (21–29) 22 (18–30) 0.68
Albumin, g/dL 3.65 (3.00–3.80) 3.75 (3.10–3.80) 3.47 (3.05–3.80) 0.65
Calcium, mg/dL 8.9 (8.7–9.2) 8.9 (8.7–9.3) 8.9 (8.4–9.1) 0.76
Phosphate, mg/dL 5.1 (4.2–5.8) 5.1 (3.7–6.2) 5.1 (4.8–5.4) 0.79
PTH, pg/mL 398 (104–658) 408 (116–618) 398 (162–675) 0.58
Arterial pH 7.32 (7.28–7.35) 7.33 (7.30–7.37) 7.31 (7.27–7.35) 0.45
Sodium, mEq/L 136 (135–139) 137 (135–139) 136 (135–137) 0.57
Potassium, mEq/L 5.0 (4.7–5.3) 4.9 (4.4–5.2) 5.0 (4.8–5.4) 0.60
Bicarbonate, mEq/L 20.2 (18.4–23.3) 22.0 (18.5–23.6) 19.0 (18.5–22.9) 0.73
ALT, UI/L 18 (17–24) 17 (16–22) 18 (17–30) 0.54
AST, UI/L 13 (11–21) 13 (11–20) 12 (12–19) 0.97
Switch over (3 months)
Haemoglobin, g/dL 11.8 (11.0–12.3) 12.1 (10.9–12.4) 11.7 (11.5–12.3) 0.71
Haematocrit, vol% 37.8 (35.4–40.0) 38.5 (35.4–39.9) 37.2 (36.1–40.0) 1.00
MCV, fL 100 (93–103) 98 (93–103) 100 (94–102) 0.87
WBC, 103/mL 7.54 (6.25–9.33) 6.87 (5.81–8.16) 8.38 (6.58–9.65) 0.22
Platelets, 103/mL 207 (188–278) 192 (150.5–283) 217 (202–254) 0.31
Ferritin, ng/mL 225 (56–431) 191 (65–364) 290 (55–443) 0.72
Iron, mg/dL 50 (41–60) 51 (44–57) 48 (37–60) 0.74
Iron saturation, % 21 (14–25) 20 (15–24) 21 (14–25) 0.97
Albumin, g/dL 3.70 (3.30–3.95) 3.60 (3.35–3.80) 3.80 (3.30–4.20) 0.37
Calcium, mg/dL 9.0 (8.6–9.5) 9.3 (8.6–9.5) 8.7 (8.7–9.0) 0.57
Phosphate, mg/dL 5.0 (3.8–6.6) 5.0 (3.4–6.3) 5.4 (4.0–6.4) 0.65
PTH, pg/mL 541 (166–774) 543 (203–660) 541 (144–804) 0.45
Arterial pH 7.31 (7.30–7.37) 7.31 (7.30–7.38) 7.32 (7.31–7.36) 0.84
Sodium, mEq/L 137 (136–139) 137 (136–138) 136 (136–140) 0.68
Potassium, mEq/L 4.8 (4.6–5.2) 4.7 (4.6–5.0) 5.2 (4.8–5.5) 0.10
Bicarbonate, mEq/L 20.1 (19.1–21.1) 20.1 (19.0–20.9) 20.1 (19.3–21.0) 0.97
ALT, UI/L 21 (16–25) 19 (14–22) 21 (17–26) 0.37
AST, UI/L 15 (12–20) 17 (11–20) 14 (13–19) 0.90
End of study (6 months)
All (n¼ 20) Group A (n¼ 10) Group B (n¼ 8)
Haemoglobin, g/dL 10.4 (9.9–11.3) 10.8 (9.6–11.3) 10.3 (10.1–11.2) 0.93
Haematocrit, vol% 32.9 (31.7–36.2) 34.1 (31.6–36.0) 32.6 (32–35) 0.57
MCV, fL 100 (95–103) 100 (96–103) 99 (94–102) 0.79
WBC, 103/mL 5.99 (5.45–8.00) 5.71 (4.81–8.44) 6.88 (5.89–7.88) 0.37
Platelets, 103/mL 182 (143.5–244.2) 161.5 (117–297.8) 199.5 (148–242.8) 0.63
Ferritin, ng/mL 339 (142–534) 190 (138–459) 432 (273–561) 0.25
Iron, mg/dL 59 (49–79) 54 (43–60) 72 (63–82) 0.11
Iron saturation, % 26 (22–37) 22 (19–25) 36 (27–41) 0.01
Albumin, g/dL 3.50 (3.40–3.85) 3.50 (3.43–3.70) 3.6 (2.98–3.90) 1.00
Calcium, mg/dL 9.2 (8.8–9.4) 9.3 (8.9–9.4) 9.1 (7.7–9.4) 0.47
Phosphate, mg/dL 4.6 (3.7–6.2) 4.6 (3.9–5.5) 4.8 (3.5–6.5) 0.89
PTH, pg/mL 248 (135–474) 167 (128–363) 287 (210–704) 0.32
Arterial pH 7.34 (7.32–7.37) 7.35 (7.33–7.40) 7.32 (7.29–7.37) 0.17
Sodium, mEq/L 137 (135–139) 138 (136–139) 136 (133–139) 0.82
Potassium, mEq/L 5.1 (4.5–5.4) 5.1 (4.7–5.3) 4.9 (4.4–5.5) 0.97
Bicarbonate, mEq/L 22.0 (21.0–23.4) 22.1 (21.5–23.5) 21.7 (18.6–22.6) 0.26
ALT, UI/L 20 (16–22) 19 (16–22) 20 (18–28) 0.50
AST, UI/L 14 (12–16) 14 (11–16) 15 (12–17) 0.82
Data are presented as median (IQR). P-values refer to difference between Groups A and B at each month (Mann–Whitney U test).
ALT, alanine transaminase; AST, aspartate transaminase; MCV, mean corpuscular volume; PTH, parathyroid hormone; WBC, white blood cells.
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following two classes: none or one or more episode/patient. The
total number of hospitalizations was higher during treatment
with HD than with HDx (n¼ 11/19 versus n¼ 8/19; P¼ 0.53).
Hospitalization rate was also higher in Group B than in Group A
for both arms of the study (Figure 4C). In a logistic regression
model, HD was associated with a non-significant increase in the
risk of hospitalization (OR 5.99, 95% CI 0.811–44.221; P¼ 0.079).
DISCUSSION
The main finding that emerged from this study confirmed that
chronic HD with MCO membranes is not associated with hypo-
albuminaemia. Indeed, the reduction in median level of albumi-
naemia in patients of Group B during the second part of the
study [from 3.8 (3.3–4.2) g/dL to 3.6 (2.98–3.9) g/dL] was not asso-
ciated with treatment after multivariate analysis. Moreover,
this reduction did not appear to have any clinical relevance.
This result is consistent with other studies. Zickler et al. [12] de-
scribed a reduction in albumin levels during the first 4 weeks of
treatment with HDx, followed by an increase during the subse-
quent 8 weeks of the same treatment. Instead, no differences in
mean albumin levels were found in other studies undertaken by
Ronco et al. [13], Teatini and Longhena [14], Belmouaz et al. [15]
and Arrascue et al. [16].
Therefore, we can hypothesize that the quantity of albumin
lost during HDx (estimated by Baxter as 1.2–3.9 g/treatment) can
easily be replaced by hepatic synthesis and could also be benefi-
cial for CKD patients in whom high levels of urea can promote
carbamylation of serum albumin. Carbamylated albumin may
be considered as a uraemic toxin since it seems to be associated
with higher mortality, accelerated renal fibrosis and higher
erythropoietin resistance in patients with ESRD [9, 17, 18].
FIGURE 4: Frequency of (A) hypotensive events, (B) infections and (C) hospital-
izations in Groups A and B following HD and HDx treatments.
FIGURE 2: Change in albuminaemia in Groups A and B during treatment with
HDx and HD. Values are presented as median (IQR).
FIGURE 3: Levels of (A) IL-1b and (B) IL-6 prior to and after HD and HDx treat-
ments. Data are presented as mean and standard error of the mean.
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The other important result that emerged from our study was
the difference in the incidence of infections during the two dif-
ferent treatments. Although difficult to interpret, because of the
small sample size and potential bias, this result is very encour-
aging since infectious diseases are the most common cause of
hospitalization and the second most common cause of death in
HD patients [3, 19]. These patients are more prone to infections
than the general population, mainly because of the high preva-
lence of diabetes mellitus, the presence of an indwelling cathe-
ter and a condition of acquired immune dysfunction due to the
retention of uraemic toxins and chronic inflammation.
We can propose different pathways through which HDx could
play a role in reducing the rate of infections in HD patients. One
of these is that treatment with MCO membranes may reduce
inflammation, as supported by the lowering of the concentration
of inflammatory cytokines in our patients undergoing HDx.
These findings are consistent with results of previous studies in
which HDx appeared to be associated with a lowering of the con-
centration of C-reactive protein [20] and the reduction of tran-
scription of pro-inflammatory cytokines in peripheral leucocytes
[12]. Another possible explanation for the decrease of infectious
events could be that HDx reduces serum concentration of free
light chains, since their retention in CKD patients is associated
with in vitro inhibition of leucocytes chemotaxis [21].
In addition to an improvement in the immunological re-
sponse, lower concentrations of inflammatory cytokines induced
by treatment with MCO membranes may also lead to other bene-
ficial effects in patients with ESRD. In these patients, systemic in-
flammation is associated with increased mortality due to
cardiovascular disease, and with osteoporosis, depression, meta-
bolic and nutritional derangements, and poor quality of life
[22, 23]. In particular, there is strong evidence linking chronic in-
flammation to the development of cardiovascular diseases.
Indeed, IL-1b seems to be associated with left ventricular hyper-
trophy in dialysis patients [24] and with the progression of ath-
erosclerosis in patients with ischaemic heart disease, in whom
serum concentrations of IL-1b correlate with plaque severity [25].
Elevated levels of IL-6 are also associated with cardiovascular
mortality and left ventricular hypertrophy in HD patients [26].
The present data revealed a non-significant trend towards
higher risk of hospitalization with HD. However, the incidence
of hospitalizations remains difficult to interpret due to the
global higher hospitalization rate observed within Group B and
to the weak clinical relationship linking the causes of hospitali-
zation to dialysis modality. Although there was slightly higher
incidence of symptomatic hypotensive events in the HDx group
(8 events versus 5 events), the total number of absent/low hypo-
tensive events was 11 in the HD group versus 9 in the HDx
group, and both groups had the same number of moderate or
high hypotensive events (n¼ 9). The risk of hypotension in
patients, particularly with cardiovascular disease, should be
monitored, independent of dialysis type. A larger sample size
will be needed to verify whether hypotension rate could be dif-
ferent among different dialysis methods.
Limitations
Limitations of our study include the small sample size, high
number of drop-outs, absence of a wash-out period prior to
switching treatment with no possibility to correct for any poten-
tial carry-over effect. In addition, parameters of dialysis ade-
quacy suggested under-treatment and uncontrolled medical
therapies for anaemia, CKD-MBD, hypertension and water
balance.
Conclusions and future perspectives
Despite these limitations, this study allowed us to confirm the
safety and tolerability of HDx chronic treatment over a period of
3 months. Furthermore, it validated the ability of these new
membranes to reduce the serum concentration of soluble in-
flammatory mediators. Modulating inflammation, chronic HDx
treatment may play a key role in improving immunological
function and reducing cardiovascular burden in HD patients.
These results encourage further trials with longer treatment
periods and larger sample size.
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